The chemotherapy response score (CRS): Interobserver reproducibility in a simple and prognostically relevant system for reporting the histologic response to neoadjuvant chemotherapy in Tuboovarian High-grade Serous Carcinoma

International Journal of Gynecological Pathology

Volumn 36, Issue 2, 2017, Pages 172-179

  Said, Ian ^a   Böhm, Steffen ^a   Beasley, Joanne ^d   Ellery, Peter ^b,c   Faruqi, Asma Z ^a   Ganesan, Raji ^d   Hirschowitz, Lynn ^d   Jeetle, Sharanpal ^a   Leen, Sarah Lam Shang ^a   McCluggage, W Glenn ^d   McDermott, Jacqueline ^a   Merard, Reena ^a   Millner, Thomas O ^a   Trevisan, Giorgia ^b,c   Vella, Jo ^c   Gilks, C Blake ^e   Singh, Naveena ^a  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c BIRMINGHAM CHILDREN S HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d ROYAL VICTORIA HOSPITAL   (United Kingdom)

^e VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Chemotherapy; Chemotherapy response score; High grade serous carcinoma; Prognosis; Reproducibility

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CHEMOTHERAPY RESPONSE SCORE; CLINICAL ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; OVARY CARCINOMA; PATHOLOGIST; PRIORITY JOURNAL; REPRODUCIBILITY; SCORING SYSTEM; TREATMENT RESPONSE; TUBOOVARIAN HIGH GRADE SEROUS CARCINOMA; ADJUVANT CHEMOTHERAPY; CYSTADENOCARCINOMA, SEROUS; NEOADJUVANT THERAPY; OBSERVER VARIATION; ONCOLOGY; OVARIAN NEOPLASMS; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

CHEMOTHERAPY, ADJUVANT; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; MEDICAL ONCOLOGY; NEOADJUVANT THERAPY; OBSERVER VARIATION; OVARIAN NEOPLASMS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84976580352     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0000000000000307     Document Type: Article

References (21)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v10, Cancer Incidence and Mortality Worldwide: IARC Cancer-Base No11[internet]. Lyon, France: International Agency for Research on Cancer; 2013.
2. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-53.
3. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386: 249-57.
4. Ledermann JA, Raja FA, Fotopolou C, et al. New diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24: Vi24-32.
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 3, 2014. Available at: Http://www.nccn.org.
6. Winter WE, III, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 3621-7.
7. Rustin GJ, Vergote I, Eisenhauer E, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011; 21: 419-23.
8. Bohm S, Faruqi AZ, Said I, et al. Chemotherapy Response Score: Development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma. J Clin Oncol 2015; 33: 2457-63.
9. Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19-23.
10. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma: Clinicopathologic correlations. Cancer 1994; 73: 2680-6.
11. Chetty R, Gill P, Govender D, et al. International study group on rectal cancer regression grading: Interobserver variability with commonly used regression grading systems. Hum Pathol 2012; 43: 1917-23.
12. Le T, Williams K, Senterman M, et al. Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Gynecol Oncol 2007; 106: 160-3.
13. Sassen S, Schmalfeldt B, Avril N, et al. Histopathologic assessment of tumour regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Hum Pathol 2007; 38: 926-34.
14. Petrillo M, Zannoni GF, Tortorella L, et al. Prognostic role and predictors of complete pathological response to neoadjuvant chemotherapy in primary unresectable ovarian cancer. Am J Obstet Gynecol 2014; 211: 632.e1-8.e1.
15. Muraji M, Sudo T, Iwasaki S, et al. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery. Gynecol Oncol 2013; 132: 531-4.
16. McCluggage WG, Judge MJ, Clarke BA, et al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: Recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol 2015; 28: 1101-22.
17. College of American Pathologists. Protocol for the examination of specimens from patients with primary tumors of the ovary or fallopian tube. 2016. Available at: Http://www. cap.org.
18. Ditzel HM, Stickland K, Meserve E, et al. Assessment of the Chemotherapy Response Score (CRS) system in high grade serous carcinoma (HGSC). Mod Pathol 2016; 29(S2): 281A.
19. Lengyel E. Ovarian cancer developments and metastasis. Am J Pathol 2010; 177: 1053-64.
20. Reyes MC, Arnold AG, Kauff ND, et al. Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency. Mod Pathol 2014; 27: 1405-11.
21. Seidman JD, Vang R, Ronnett BR, et al. Distribution and case-fatality ratios by cell-Type for ovarian carcinomas: A 22-year series of 562 patients with uniform current histological classification. Gynecol Oncol 2015; 136: 336-40.